Novartis Pursues Disease-Modifying Differentiator For Cosentyx In Psoriasis
New extension data suggesting that Novartis's IL-17A inhibitor Cosentyx could alter the course of disease in its lead indication of psoriasis could position the drug earlier in the treatment paradigm and please payers; the company has launched a new prospective study to see if the results hold true.
You may also be interested in...
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.
The European Commission has approved two new drugs for psoriasis: Novartis's Cosentyx (secukinumab) and Celgene's Otezla (apremilast).
Johnson & Johnson's Stelara (ustekinumab) has received its second drubbing in recent weeks in head-to-head studies with rival anti-inflammatories in plaque psoriasis. Novartis says that top-line data from the Phase III CLEAR study show that its new anti-IL17A monoclonal secukinumab (Cosentyx) was better than Stelara in clearing the skin, and it met its primary endpoint.